Global Preventable Vaccines Market 2015-2019

Global Preventable Vaccines Market 2015-2019

Category : Pharmaceuticals
Published On : February  2015
Pages : 137



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

About Preventable Vaccines
Vaccines can be defined as a product that stimulates a person’s immune system to produce immunity to a specific disease, thereby protecting the person from that disease. According to the CDC, vaccines are usually administered through needle injections, but can also be administered orally or sprayed into the nose. Vaccines can be used for both adults and infants and adolescents. Pediatric vaccines are used for the immunization of children to give protection against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. According to the classification adopted by the US FDA, children are classified as newborn, infant, and adolescent, ranging from birth to 21 years of age.  However, the EMA classifies pediatrics as ranging from birth to 18 years of age. 

TechNavio's analysts forecast the Global Preventable Vaccines market to grow at a CAGR of 10.16 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Preventable Vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of preventable vaccines. The report examines the market for vaccines used in humans. It covers only commercialized vaccines for diseases that are vaccine preventable. 

The report does not cover emerging vaccines for diseases that are not currently vaccine preventable, such as Ebola infection, Epstein-Ban virus infection, Alzheimer's disease, diabetes, Helicobacter pylori infection, multiple sclerosis, Parkinson's disease, or West Nile virus infection.

The report has broadly categorized preventable vaccines into two major segments: 
• Adult Preventable Vaccines
• Pediatric Preventable Vaccines

TechNavio's report, the Global Preventable Vaccines Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Preventable Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
• Americas 
• APAC
• EMEA
        
Key Vendors
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer
• Sanofi 

Other Prominent Vendors
 • Abbott
• AstraZeneca
• Bavarian Nordic
• Baxter
• Bharat Biotech
• Bharat Immunologicals and Biologicals 
• bioCSL
• Bio Med 
• Crucell
• Dynavax Technologies
• Indian Immunologicals
• Janssen Pharmaceuticals
• Kaketsuken
• LG Life Sciences
• Mitsubishi Tanabe Pharma
• Lupin
• Nuron 
• Protein Sciences
• Panacea Biotec
• Roche
• Serum Institute of India 
• Shenzhen Kangtai Biological Products 
• Serum Institute of India
• Sinovac Biotech
• S K Chemicals
• Takeda Pharmaceutical 
• Valeant Pharmaceuticals
• Zydus Cadila 

Market Driver
• Inclusion in NIP
• For a full, detailed list, view our report

Market Challenge
• Inadequate Vaccine Coverage
• For a full, detailed list, view our report

Market Trend
• Increase in Strategic Alliances
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Vaccine Approval Process

07. Market Landscape

07.1 Market Overview

07.2 Market Size and Forecast

07.3 Global Adult and Pediatric Preventable Vaccine Market Share 2014-2019

07.4 Five Forces Analysis

08. Market Segmentation by Type of Vaccine

08.1 Live Attenuated Vaccine

08.2 Killed Vaccine

08.3 Toxoid Vaccine

08.4 Genetically Modified/Engineered Vaccine

09. Market Segmentation by Product Type

09.1 Polysaccharide Vaccines

09.2 Conjugate Vaccines

10. Geographical Segmentation

11. Global Preventable Vaccines Market by Key Geographies

11.1 Market Size and Forecast for the US

11.2 Market Size and Forecast for the EU

11.3 Market Size and Forecast for Japan

11.4 Market Size and Forecast for India

11.5 Market Size and Forecast for China

12. Global Pediatric Preventable Vaccines Market

12.1 Global Pediatric Preventable Vaccine Market

12.1.1 Market Size and Forecast

12.2 Market Segmentation of the Global Pediatric Preventable Vaccine Market

12.3 Global Pediatric Hepatitis Vaccines Market

12.3.1 Market Size and Forecast

12.4 Global Pediatric Haemophilus Influenzae Type B (Hib) Vaccines Market

12.4.1 Market Size and Forecast

12.5 Global Pediatric MMR Vaccines Market

Market Size and Forecast

12.6 Global Pediatric Combination Vaccines Market

12.6.1 Market Size and Forecast

12.7 Global Pediatric Pneumococcal Vaccines Market

12.7.1 Market Size and Forecast

12.8 Global Polio Vaccines Market

12.8.1 Market Size and Forecast

12.9 Global Pediatric Varicella Vaccines Market

12.9.1 Market Size and Forecast

12.10 Global Other Pediatric Vaccines Market

12.10.1 Market Size and Forecast

12.11 Global Pediatric Preventable Vaccines Market 2014 and 2019 (by percentage)

13. Global Adult Preventable Vaccines Market 

13.1 Market Size and Forecast

13.2 Market Segmentation of the Global Adult Preventable Vaccines Market

13.3 Global Adult Cervical Vaccines Market

13.3.1 Market Size and Forecast

13.4 Global Adult Hepatitis Vaccines Market

13.4.1 Market Size and Forecast

13.5 Global Adult Influenza Vaccines Market

13.5.1 Market Size and Forecast

13.6 Global Adult Pneumococcal Vaccines Market

13.6.1 Market Size and Forecast

13.7 Global Adult Travel, Diphtheria-Tetanus, and Miscellaneous Vaccines Market

13.7.1 Market Size and Forecast

14. Key Leading Countries

14.1 US

14.2 China

14.3 Japan

14.4 India 

15. Buying Criteria

16. Market Growth Drivers

17. Drivers and their Impact

18. Market Challenges

19. Impact of Drivers and Challenges

20. Market Trends

21. Trends and their Impact

22. Vendor Landscape

22.1 Competitive Scenario

22.1.1 Key News

22.1.2 Mergers and Acquisitions

22.2 Market Share Analysis 2014

22.2.1 GlaxoSmithKline

22.2.2 Merck

22.2.3 Novartis

22.2.4 Pfizer

22.2.5 Sanofi

22.3 Other Prominent Vendors

23. Key Vendor Analysis

23.1 GlaxoSmithKline

23.1.1 Key Facts

23.1.2 Business Overview

23.1.3 Business Segmentation

23.1.4 Business Segmentation by Revenue 2012 and 2013

23.1.5 Sales by Geography

23.1.6 Pipeline Products

23.1.7 Business Strategy

23.1.8 Key Information

23.1.9 SWOT Analysis

23.2 Merck

23.2.1 Key Facts

23.2.2 Business Overview

23.2.3 Business Segmentation by Revenue 2013

23.2.4 Business Segmentation by Revenue 2012 and 2013

23.2.5 Sales by Geography

23.2.6 Business Strategy

23.2.7 Key Developments

23.2.8 SWOT Analysis

23.3 Novartis

23.3.1 Key Facts

23.3.2 Business Description

23.3.3 Business Segmentation

23.3.4 Revenue by Business Segmentation

23.3.5 Revenue Comparison 2012 and 2013

23.3.6 Sales by Geography

23.3.7 Business Strategy

23.3.8 Key Developments

23.3.9 SWOT Analysis

23.4 Pfizer

23.4.1 Key Facts

23.4.2 Business Overview

23.4.3 Business Segmentation by Revenue 2013

23.4.4 Business Segmentation by Revenue 2012 and 2013

23.4.5 Geographical Segmentation by Revenue

23.4.6 Business Strategy

23.4.7 Key Developments

23.4.8 SWOT Analysis

23.5 Sanofi

23.5.1 Key Facts

23.5.2 Business Description

23.5.3 Business Segmentation

23.5.4 Revenue by Business Segmentation

23.5.5 Revenue Comparison 2012 and 2013

23.5.6 Sales by Geography

23.5.7 Business Strategy

23.5.8 Key Developments

23.5.9 SWOT Analysis

24. Other Reports in this Series 

List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Vaccine Approval Process

Exhibit 3: Global Preventable Vaccines Market 2014-2019 (US$ million)

Exhibit 4: Global Preventable Vaccines Market Categories

Exhibit 5: Global Adult and Pediatric Preventable Vaccine Market Share 2014-2019 (US$ million)

Exhibit 6: Global Preventable Vaccines Market Share by Vaccine Type 2014 and 2019

Exhibit 7: Global Preventable Vaccines Market Segmentation by Type of Vaccine

Exhibit 8: Global Preventable Vaccines Market Segmentation by Product Type

Exhibit 9: Global Preventable Vaccines Market by Geographical Segmentation 2014

Exhibit 10: Global Preventable Vaccines Market by Region 2014-2019 (US$ million)

Exhibit 11: Global Preventable Vaccines Market in the US 2014-2019 (US$ million)

Exhibit 12: Global Preventable Vaccines Market in the EU 2014-2019 (US$ million)

Exhibit 13: Global Preventable Vaccines Market in Japan 2014-2019 (US$ million)

Exhibit 14: Global Preventable Vaccines Market in India 2014-2019 (US$ million)

Exhibit 15: Global Preventable Vaccines Market in China 2014-2019 (US$ million)

Exhibit 16: Global Pediatric Preventable Vaccines Market 2014-2019 (US$ million)

Exhibit 17: Global Pediatric Preventable Vaccines Market Segmentation

Exhibit 18: Global Pediatric Hepatitis Vaccines Market 2014-2019 (US$ million)

Exhibit 19: Global Pediatric Haemophilus Influenzae Type B Vaccines Market 2014-2019 (US$ million)

Exhibit 20: Global Pediatric MMR Vaccine Market 2014-2019 (US$ million)

Exhibit 21: Global Pediatric Combination Vaccines Market 2014-2019 (US$ million)

Exhibit 22: Global Pediatric Pneumococcal Vaccines Market 2014-2019 (US$ million)

Exhibit 23: Global Polio Vaccines Market 2014-2019 (US$ million)

Exhibit 24: Global Pediatric Varicella Vaccines Market 2014-2019 (US$ million)

Exhibit 25: Global Other Pediatric Vaccines Market 2014-2019 (US$ million)

Exhibit 26: Global Pediatric Preventable Vaccines Market by Vaccine Segmentation (2014 and 2019) (US$ Million)

Exhibit 27: Global Pediatric Preventable Vaccines Market by Vaccine Segmentation 2014 (in %)

Exhibit 28: Global Pediatric Preventable Vaccines Market by Vaccine Segmentation 2019 (in %)

Exhibit 29: Snapshot of Global Pediatric Preventable Vaccines Market by Segments 2014-2019

Exhibit 30: Global Adult Preventable Vaccines Market 2014-2019 (US$ million)

Exhibit 31: Global Adult Cervical Vaccines Market 2014-2019 (US$ million)

Exhibit 32: Global Adult Hepatitis Vaccines Market 2014-2019 (US$ million)

Exhibit 33: Global Adult Influenza Vaccine Market 2014-2019 (US$ million)

Exhibit 34: Global Adult Pneumococcal Vaccines Market 2014-2019 (US$ million)

Exhibit 35: Global Travel, Diphtheria-Tetanus, and Miscellaneous Vaccines Market 2014-2019 (US$ million)

Exhibit 36: Global Adult Preventable Vaccines Market by Vaccine Segmentation (2014 and 2019) (US$ Million)

Exhibit 37: Global Adult Preventable Vaccines Market by Vaccine Segmentation 2014 (in %)

Exhibit 38: Global Adult Preventable Vaccines Market by Vaccine Segmentation 2019 (in %)

Exhibit 39: Snapshot of Global Adult Preventable Vaccines Market by Segments 2014-2019

Exhibit 40: Buying Criteria of the Global Preventable Vaccines Market

Exhibit 41: Drivers and their Impact on the Key Customer Category of the Global Preventable Vaccines Market

Exhibit 42: Drivers and their Impact on Geographies in Global Preventable Vaccines Market

Exhibit 43: GlaxoSmithKline's Revenue 2013

Exhibit 44: GlaxoSmithKline: Vaccine Pipeline

Exhibit 45: Merck's Revenue 2013

Exhibit 46: Novartis' Revenue 2013

Exhibit 47: Novartis: Vaccine Pipeline

Exhibit 48: Pfizer's Revenue 2013

Exhibit 49: Sanofi's Revenue 2013

Exhibit 50: GlaxoSmithKline: Business Segmentation 2013

Exhibit 51: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)

Exhibit 52: GlaxoSmithKline: Sales by Geography 2013

Exhibit 53: GlaxoSmithKline: Pipeline Products 2013

Exhibit 54: Merck & Co. Inc.: Business Segmentation by Revenue 2013

Exhibit 55: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)

Exhibit 56: Merck & Co. Inc.: Sales by Geography 2013

Exhibit 57: Novartis AG: Business Segmentation

Exhibit 58: Novartis AG: Revenue by Business Segmentation 2013

Exhibit 59: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)

Exhibit 60: Novartis AG: Revenue by Geographical Segmentation 2013

Exhibit 61: Pfizer: Business Segmentation by Revenue 2013

Exhibit 62: Pfizer: Business Segmentation by Revenue 2012 and 2013

Exhibit 63: Pfizer: Geographical Segmentation by Revenue 2013

Exhibit 64: Sanofi SA: Business Segmentation

Exhibit 65: Sanofi SA: Revenue by Business Segmentation 2013

Exhibit 66: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)

Exhibit 67: Sanofi SA: Sales Revenue by Geographical Segmentation 2013 



Enquiry Before Buy